Navegar por autor "Xicoy, B."

Mostrando ítems 1-9 de 9

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

2024- Mosquera Orgueira, Adrián; Arellano-Rodrigo, E.; Garrote, M.; Martín, I.; Pérez Encinas, Manuel Mateo; [et al.]
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

2023- Mosquera Orgueira, Adrián; Pérez Encinas, Manuel Mateo; Diaz Varela, N.A.; Mora, E.; Díaz-Beyá, M.; [et al.]
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

2023- Mosquera Orgueira, Adrián; Pérez Encinas, Manuel Mateo; Diaz Varela, N.A.; Mora, E.; Díaz-Beyá, M.; [et al.]
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

2023- Mosquera Orgueira, Adrián; Pérez Encinas, Manuel Mateo; Hernández-Sánchez, A.; González Martínez, María Teresa; Arellano-Rodrigo, E.; [et al.]
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

2020- Hernández-Boluda, J.-C.; Pereira, A.; Alvarez-Larran, A.; Martín, A.-A.; Benzaquen, A.; [et al.]
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

2025- Pérez-Lamas, L.; Segura Diaz, A.; García Delgado, R.; Álvarez-Larrán, A.; Senin, M.A.; [et al.]
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

2022- Luna, A.; Pérez-Lamas, L.; Boque, C.; Giraldo, P.; Xicoy, B.; [et al.]
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

2021- Garcia-Gutiérrez, V.; Luna, A.; Alonso-Dominguez, J.M.; Estrada, N.; Boque, C.; [et al.]
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

2023- Pérez-Lamas, L.; Luna, A.; Boque, C.; Xicoy, B.; Giraldo, P.; [et al.]